Authors: Campos, SM Penson, RT Mays, AR Berkowitz, RS Fuller, AF Goodman, A Matulonis, UA Muzikansky, A Seiden, MV

Citation: Sm. Campos et al., The clinical utility of liposomal doxorubicin in recurrent ovarian cancer, GYNECOL ONC, 81(2), 2001, pp. 206-212

Authors: Penson, RT Supko, JG Seiden, MV Fuller, AF Berkowitz, RS Goodman, A Campos, SM MacNeill, KM Cook, S Matulonis, UA

Citation: Rt. Penson et al., A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Mullerian tumors, CANCER, 92(5), 2001, pp. 1156-1167

Authors: Penson, RT Kronish, K Duan, Z Feller, AJ Stark, P Cook, SE Duska, LR Fuller, AF Goodman, AK Nikrui, N MacNeill, KM Matulonis, UA Preffer, FI Seiden, MV

Citation: Rt. Penson et al., Cytokines IL-1 beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNF alpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel, INT J GYN C, 10(1), 2000, pp. 33-41

Authors: Burstein, HJ Manola, J Younger, J Parker, LM Bunnell, CA Scheib, R Matulonis, UA Garber, JE Clarke, KD Shulman, LN Winer, EP

Citation: Hj. Burstein et al., Docetaxel administered on a weekly basis for metastatic breast cancer, J CL ONCOL, 18(6), 2000, pp. 1212-1219

Authors: Burstein, HJ Ramirez, MJ Petros, WP Clarke, KD Warmuth, MA Marcom, PK Matulonis, UA Parker, LM Harris, LN Winer, EP

Citation: Hj. Burstein et al., Phase I study of Doxil and vinorelbine in metastatic breast cancer, ANN ONCOL, 10(9), 1999, pp. 1113-1116

Authors: Havlin, KA Ramirez, MJ Legler, CM Harris, LN Matulonis, UA Hohneker, JA Hayes, DF Winer, EP

Citation: Ka. Havlin et al., Inability to escalate vinorelbine dose intensity using a daily x3 schedulewith and without filgrastim in patients with metastatic breast cancer, CANC CHEMOT, 43(1), 1999, pp. 68-72